

**VEO, WP9&10: Identification of barriers and lessons learnt in the development and implementation of tools to fight SARS-CoV-2 questionnaire**

1. From which sector does your institute primarily belongs to?

- Research Institute/University
- Government agency
- Private sector
- NGO
- Other

2. What type of scientific tool have you applied to SARS-CoV-2?

- Diagnostic
- Sequencing
- Epidemiological/ statistical analyses
- Modelling/ risk assessment
- Laboratory (*In vitro*) experiments
- Animal experiments
- Vaccine/ drug trials
- Other

3. Further info on tool:

For example material being sampled / sequence; outputs of analyses etc. Include reference if possible.

4. What is the main purpose of your tool?

- Patient diagnosis
- Outbreak monitoring
- Outbreak control
- Fundamental research
- Vaccine/ treatment development
- Other

Elaborate how it supports COVID-19 response.

5. What data and /or depositories were used in the development of your tool?

- A. National epidemiological data
- B. International epidemiological data
- C. National laboratory data
- D. International laboratory data
- E. VEO hub
- F. GISAIID
- G. Etc.

Please provide further information regarding which data sets.

6. Speed

at which the tool was developed / deployed for SARS-COV2?

- A. 0-3 days
- B. 3-7 days
- C. 7-14 days
- D. >14 days

7. Cost of development/deployment of the tool?

- A. Low (<10k)
- B. Medium (10-100k)
- C. High (100-500K)
- D. Very high (>500k)

8. Impact of the tool on the control of SARS-COV2 during the current pandemic; high, medium low.

- High: Results directly used by Govt to inform control policy
- Medium: Results indirectly used by Govt to inform control policy
- Low: Results not used by Govt to inform control policy

9. Impact of the tool on the control of SARS-COV2 in a future pandemic; high, medium, low.

- High: Results directly used by Govt to inform control policy
- Medium: Results indirectly used by Govt to inform control policy
- Low: Results not used by Govt to inform control policy

10. Availability of tool / material / outputs to others in VEO consortium.

- Yes
- No

11. Availability of tool / material / outputs to others outside the VEO consortium.

- Yes
- No

12. If yes to Q11, how can the tool / material / outputs be accessed?

- A. Code on GITHUB
- B. Sequences on GISAIID
- C. Etc. etc.
- Etc.

13. For each tool, what are the lessons learnt for next pandemic?

Tool	Lessons Learnt
Insert tool	
Insert tool	
Insert tool	
Insert tool	

14. Are there barriers to applying this tool? (Not only for activities within VEO, but also within your organization) e.g. access to data, sharing of samples.

Insert tool	Choose an item.
Insert tool	Choose an item.
Insert tool	Choose an item.

Insert tool	Choose an item.
-------------	-----------------

15. Provide details of the barriers on the following points:

<i>How it hampered the application of the tool?</i>	
<i>Were the barriers for accessing (from whom/where?) or sharing (at which level?) data/materials?</i>	
<i>Which type of barrier? (e.g. institutional policies, EU regulation, political issues, ethical standards)</i>	
<i>Please, specify the barriers for the type of data/materials/output.</i>	

16. For each tool, do you see any possible ways of addressing these barriers (i) within or (ii) outside VEO?

- Yes – within VEO
- Yes – outside VEO
- Yes – within & outside VEO
- No
- Don't know

If yes, are these:

- Technical solutions (e.g. protection mechanisms)
- Policy/legal solutions (e.g. standardization of policies, legal reforms)

Please provide further details.